Molecular Pharmacology (USA) Ltd. is a shell company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2005-05-20. The firm is not engaged in any business activities.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
06/30/2014
06/30/2013
06/30/2012
06/30/2011
06/30/2010
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
0
0
0
0
0
0
Research & Development
--
--
--
--
--
--
Operating Expenses
0
0
0
0
0
0
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
0
0
0
0
0
0
Income Tax Expense
0
0
0
0
0
0
Net Income
0
0
0
0
0
0
Net Income Growth
--
--
--
--
--
--
Shares Outstanding (Diluted)
111.55
111.55
111.55
111.55
111.55
111.55
Shares Change (YoY)
0%
0%
0%
0%
0%
0%
EPS (Diluted)
0
0
0
0
0
0
EPS Growth
125%
-42%
19%
45%
0%
22%
Free Cash Flow
0
0
0
0
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
0
0
0
0
0
0
EBITDA Margin
0%
0%
0%
0%
0%
0%
D&A For EBITDA
0
0
0
0
0
0
EBIT
0
0
0
0
0
0
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
0%
0%
0%
0%
0%
0%
Follow-Up Questions
What are Molecular Pharmacology (USA) Ltd's key financial statements?
According to the latest financial statement (Form-10K), Molecular Pharmacology (USA) Ltd has a total asset of $0, Net loss of $0
What are the key financial ratios for MLPH?
Molecular Pharmacology (USA) Ltd's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Molecular Pharmacology (USA) Ltd's revenue broken down by segment or geography?
Molecular Pharmacology (USA) Ltd largest revenue segment is Bitcoin Mining Data Centers, at a revenue of 151,270,000 in the most earnings release.For geography, United States is the primary market for Molecular Pharmacology (USA) Ltd, at a revenue of 151,270,000.
Is Molecular Pharmacology (USA) Ltd profitable?
no, according to the latest financial statements, Molecular Pharmacology (USA) Ltd has a net loss of $0
Does Molecular Pharmacology (USA) Ltd have any liabilities?
yes, Molecular Pharmacology (USA) Ltd has liability of 2
How many outstanding shares for Molecular Pharmacology (USA) Ltd?
Molecular Pharmacology (USA) Ltd has a total outstanding shares of 111.55